Bempedoic acid (BA) is a novel first-in-class oral lipid-lowering therapy. BA has been approved by the European Medicinal Agency and Food and Drug Administration and has been commercialised throughout Europe since the end of 2020 as an add-on therapy in patients at high/very-high cardiovascular risk that are not at LDL-C goals with current lipid-lowering treatments. Recently, Italian lipid management experts gathered to discuss several open questions on BA characteristics and BArelated practical clinical issues. The panel permitted collection of its opinions in a ten Q&A format. Aim: The aim of this viewpoint is to discuss and answer several open questions on BA characteristics and BA-related practical clinical issues. Data synthesis: The data includes main phase III studies, subanalysis and meta-analysis on BA. Conclusions: The panel permitted collection of its opinions in a ten Q&A format.
Clinical evaluation of bempedoic acid for the treatment of hyperlipidaemia / Averna, M.; Bilato, C.; Sesti, G.. - In: NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES. - ISSN 0939-4753. - 32:1(2022), pp. 17-20. [10.1016/j.numecd.2021.09.023]
Clinical evaluation of bempedoic acid for the treatment of hyperlipidaemia
Sesti G.Ultimo
Writing – Original Draft Preparation
2022
Abstract
Bempedoic acid (BA) is a novel first-in-class oral lipid-lowering therapy. BA has been approved by the European Medicinal Agency and Food and Drug Administration and has been commercialised throughout Europe since the end of 2020 as an add-on therapy in patients at high/very-high cardiovascular risk that are not at LDL-C goals with current lipid-lowering treatments. Recently, Italian lipid management experts gathered to discuss several open questions on BA characteristics and BArelated practical clinical issues. The panel permitted collection of its opinions in a ten Q&A format. Aim: The aim of this viewpoint is to discuss and answer several open questions on BA characteristics and BA-related practical clinical issues. Data synthesis: The data includes main phase III studies, subanalysis and meta-analysis on BA. Conclusions: The panel permitted collection of its opinions in a ten Q&A format.| File | Dimensione | Formato | |
|---|---|---|---|
|
Clinical evaluation of bempedoic acid NMCD 2022.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
228.5 kB
Formato
Adobe PDF
|
228.5 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
